PURPOSE: The use of [18F]fluoroethyl)-L-tyrosine ([18F]FET) positron emission tomography/computed tomography (PET/CT) has proven valuable in brain tumor management. This study aimed to investigate the prognostic value of radiotracer uptake in newly diagnosed grade II or III gliomas according to the current 2016 World Health Organization (WHO) classification. PROCEDURES: A total of 35 treatment-naive patients (mean age, 48 ± 17 years) with histologically proven WHO grade II or III gliomas as defined by the current 2016 WHO classification were included. Static PET/CT imaging was performed 20 min after intravenous [18F]FET injection. Images were assessed visually and semi-quantitatively using regions of interest for both tumor (SUVmax, SUVmean) and background (BKGmean) to calculate tumor-to-background (TBR) ratios. The association among histological results, molecular markers (including isocitrate dehydrogenase enzyme and methylguanine-DNA methyltransferase status), clinical features (age), and PET findings was tested and compared with outcome (progression-free [PFS] and overall survival [OS]). RESULTS: Fourteen patients presented with grade II (diffuse astrocytoma n = 10, oligodendroglioma n = 4) and 21 patients with grade III glioma (anaplastic astrocytoma n = 15, anaplastic oligodendroglioma n = 6). Twenty-seven out of the 35 patients were PET-positive (grade II n = 8/14, grade III n = 19/21), with grade III tumors exhibiting significantly higher amino acid uptake (TBRmean and TBRmax; p = 0.03 and p = 0.02, respectively). PET-negative lesions demonstrated significantly prolonged PFS (p = 0.003) as compared to PET-positive gliomas. PET-positive disease had a complementary value in prognostication in addition to patient age, glioma grade, and molecular markers. CONCLUSIONS: Amino acid uptake as assessed by [18F]FET-PET/CT imaging is useful as non-invasive read-out for tumor biology and prognosis in newly diagnosed, treatment-naive gliomas according to the 2016 WHO classification.
PURPOSE: The use of [18F]fluoroethyl)-L-tyrosine ([18F]FET) positron emission tomography/computed tomography (PET/CT) has proven valuable in brain tumor management. This study aimed to investigate the prognostic value of radiotracer uptake in newly diagnosed grade II or III gliomas according to the current 2016 World Health Organization (WHO) classification. PROCEDURES: A total of 35 treatment-naive patients (mean age, 48 ± 17 years) with histologically proven WHO grade II or III gliomas as defined by the current 2016 WHO classification were included. Static PET/CT imaging was performed 20 min after intravenous [18F]FET injection. Images were assessed visually and semi-quantitatively using regions of interest for both tumor (SUVmax, SUVmean) and background (BKGmean) to calculate tumor-to-background (TBR) ratios. The association among histological results, molecular markers (including isocitrate dehydrogenase enzyme and methylguanine-DNA methyltransferase status), clinical features (age), and PET findings was tested and compared with outcome (progression-free [PFS] and overall survival [OS]). RESULTS: Fourteen patients presented with grade II (diffuse astrocytoma n = 10, oligodendroglioma n = 4) and 21 patients with grade III glioma (anaplastic astrocytoma n = 15, anaplastic oligodendroglioma n = 6). Twenty-seven out of the 35 patients were PET-positive (grade II n = 8/14, grade III n = 19/21), with grade III tumors exhibiting significantly higher amino acid uptake (TBRmean and TBRmax; p = 0.03 and p = 0.02, respectively). PET-negative lesions demonstrated significantly prolonged PFS (p = 0.003) as compared to PET-positive gliomas. PET-positive disease had a complementary value in prognostication in addition to patient age, glioma grade, and molecular markers. CONCLUSIONS: Amino acid uptake as assessed by [18F]FET-PET/CT imaging is useful as non-invasive read-out for tumor biology and prognosis in newly diagnosed, treatment-naive gliomas according to the 2016 WHO classification.
Authors: Norbert Galldiks; Karl-Josef Langen; Richard Holy; Michael Pinkawa; Gabriele Stoffels; Kay W Nolte; Hans J Kaiser; Christan P Filss; Gereon R Fink; Heinz H Coenen; Michael J Eble; Marc D Piroth Journal: J Nucl Med Date: 2012-05-29 Impact factor: 10.057
Authors: Manuel Röhrich; Kristin Huang; Daniel Schrimpf; Nathalie L Albert; Thomas Hielscher; Andreas von Deimling; Ulrich Schüller; Antonia Dimitrakopoulou-Strauss; Uwe Haberkorn Journal: Eur J Nucl Med Mol Imaging Date: 2018-05-07 Impact factor: 9.236
Authors: Nathalie L Albert; Michael Weller; Bogdana Suchorska; Norbert Galldiks; Riccardo Soffietti; Michelle M Kim; Christian la Fougère; Whitney Pope; Ian Law; Javier Arbizu; Marc C Chamberlain; Michael Vogelbaum; Ben M Ellingson; Joerg C Tonn Journal: Neuro Oncol Date: 2016-04-21 Impact factor: 12.300
Authors: Nathalie L Jansen; Bogdana Suchorska; Vera Wenter; Christine Schmid-Tannwald; Andrei Todica; Sabina Eigenbrod; Maximilian Niyazi; Jörg-Christian Tonn; Peter Bartenstein; Friedrich-Wilhelm Kreth; Christian la Fougère Journal: J Nucl Med Date: 2015-01 Impact factor: 10.057
Authors: Gabriele Pöpperl; Friedrich W Kreth; Jochen Herms; Walter Koch; Jan H Mehrkens; Franz J Gildehaus; Hans A Kretzschmar; Jörg C Tonn; Klaus Tatsch Journal: J Nucl Med Date: 2006-03 Impact factor: 10.057
Authors: Marcus Unterrainer; Florian Schweisthal; Bogdana Suchorska; Vera Wenter; Christine Schmid-Tannwald; Wolfgang P Fendler; Ulrich Schüller; Peter Bartenstein; Jörg-Christian Tonn; Nathalie L Albert Journal: J Nucl Med Date: 2016-03-31 Impact factor: 10.057
Authors: Vincent Dunet; Anastasia Pomoni; Andreas Hottinger; Marie Nicod-Lalonde; John O Prior Journal: Neuro Oncol Date: 2015-08-04 Impact factor: 12.300
Authors: David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues Journal: Acta Neuropathol Date: 2007-07-06 Impact factor: 17.088
Authors: Hiroyuki Tatekawa; Hiroyuki Uetani; Akifumi Hagiwara; Jingwen Yao; Talia C Oughourlian; Issei Ueda; Catalina Raymond; Albert Lai; Timothy F Cloughesy; Phioanh L Nghiemphu; Linda M Liau; Shadfar Bahri; Whitney B Pope; Noriko Salamon; Benjamin M Ellingson Journal: J Neurooncol Date: 2021-03-11 Impact factor: 4.130
Authors: Hiroyuki Tatekawa; Jingwen Yao; Talia C Oughourlian; Akifumi Hagiwara; Chencai Wang; Catalina Raymond; Albert Lai; Timothy F Cloughesy; Phioanh L Nghiemphu; Linda M Liau; Noriko Salamon; Benjamin M Ellingson Journal: Clin Nucl Med Date: 2020-12 Impact factor: 10.782